SC 0062
Alternative Names: SC-0062Latest Information Update: 11 Jul 2024
At a glance
- Originator Biocity Biopharmaceutics
- Class Small molecules; Urologics
- Mechanism of Action Endothelin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Diabetic nephropathies; IgA nephropathy
Most Recent Events
- 08 Jul 2024 Efficacy and adverse events data from the phase II SUCCEED-2 trial in diabetic kidney disease released by Biocity Biopharmaceutics
- 26 Feb 2024 BioCity Biopharma plans phase III trials for Diabetic nephropathies and IgA nephropathy (PO, Capsule) in 2024
- 21 Jun 2023 Phase-II clinical trials in IgA nephropathy in China (PO) (NCT05687890)